| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.14 | 0.005 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.091 | 0.005 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.005 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.006 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.085 | 0.006 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.006 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.097 | 0.006 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.007 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.091 | 0.007 |